Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15640%2F25%3A73628843" target="_blank" >RIV/61989592:15640/25:73628843 - isvavai.cz</a>

Result on the web

<a href="https://www.mdpi.com/2079-6382/14/1/1" target="_blank" >https://www.mdpi.com/2079-6382/14/1/1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/antibiotics14010001" target="_blank" >10.3390/antibiotics14010001</a>

Result language

angličtina

Original language name

Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation

Original language description

Cathelicidins are a group of cationic, amphipathic peptides that play a vital role in the innate immune response of many vertebrates, including humans. Produced by immune and epithelial cells, they serve as natural defenses against a wide range of pathogens, including bacteria, viruses, and fungi. In humans, the cathelicidin LL-37 is essential for wound healing, maintaining skin barrier integrity, and combating infections. Cathelicidins of different origins have shown potential in treating various skin conditions, including melanoma, acne, and diabetic foot ulcers. Despite their promising therapeutic potential, cathelicidins face significant challenges in clinical application. Many peptide-based therapies have failed in clinical trials due to unclear efficacy and safety concerns. Additionally, the emergence of bacterial resistance, which contradicts initial claims of non-resistance, further complicates their development. To successfully translate cathelicidins into effective clinical treatments, therefore, several obstacles must be addressed, including a better understanding of their mechanisms of action, sustainable large-scale production, optimized formulations for drug delivery and stability, and strategies to overcome microbial resistance. This review examines the current knowledge of cathelicidins and their therapeutic applications and discusses the challenges that hinder their clinical use and must be overcome to fully exploit their potential in medicine.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

10608 - Biochemistry and molecular biology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Antibiotics-Basel

ISSN

2079-6382

e-ISSN

2079-6382

Volume of the periodical

14

Issue of the periodical within the volume

1

Country of publishing house

CH - SWITZERLAND

Number of pages

54

Pages from-to

nestránkováno

UT code for WoS article

001404009300001

EID of the result in the Scopus database

2-s2.0-85215754569